Robert D. Hardie - Jul 6, 2021 Form 4 Insider Report for Acumen Pharmaceuticals, Inc. (ABOS)

Role
10%+ Owner
Signature
/s/ Katherine Denby, Attorney-in-Fact
Stock symbol
ABOS
Transactions as of
Jul 6, 2021
Transactions value $
$5,000,000
Form type
4
Date filed
7/8/2021, 06:15 PM
Previous filing
Jun 30, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABOS Common Stock Conversion of derivative security +2.95M +3288.95% 3.04M Jul 6, 2021 See footnote F1, F2
transaction ABOS Common Stock Purchase $5M +313K +10.28% $16.00 3.35M Jul 6, 2021 See footnote F2
transaction ABOS Common Stock Conversion of derivative security +658K 658K Jul 6, 2021 See footnote F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABOS Series A-1 Preferred Stock Conversion of derivative security $0 -1.63M -100% $0.00* 0 Jul 6, 2021 Common Stock 1.63M See footnote F1, F2
transaction ABOS Series B Preferred Stock Conversion of derivative security $0 -1.32M -100% $0.00* 0 Jul 6, 2021 Common Stock 1.32M See footnote F1, F2
transaction ABOS Series B Preferred Stock Conversion of derivative security $0 -658K -100% $0.00* 0 Jul 6, 2021 Common Stock 658K See footnote F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Robert D. Hardie is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
F2 The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust.
F3 The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB.